HopeStage
Back to all studies
RecruitingNCT05916339

Methylphenidate or amphetamine, followed by next-step medication, for ADHD in autistic youth

About this titleRead the official source — NCT05916339
Medication studyAges 4–17United States + Canada
The study in practice

Understand this study

Who could participate?

Listed age limits: 4 years to 17 years.

Listed locations
Irvine and 12 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: October 1, 2023
Recruitment status
Recruiting
Enrollment listed in the registry
500
Sponsor
Daniel Coury
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States, Canada
Age range
From 4 Years to 17 Years
Official registry ID
NCT05916339
Official title
Show the full official title

Comparative Effectiveness of Pharmacologic Management of ADHD in Children and Youth With Autism Spectrum Disorder

Recruitment & locations

Currently recruiting

Irvine, United States · Los Angeles, United States · Portland, United States

10 more locations
  • Boston, United States
  • Rochester, United States
  • Cincinnati, United States
  • Columbus, United States
  • Philadelphia, United States
  • Pittsburgh, United States
  • Greenville, United States
  • Charlottesville, United States
  • Edmonton, Canada
  • Toronto, Canada
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Daniel Coury.

Does this study involve medication?

Yes. The study involves medication, including Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant..

Who can participate?

Listed age limits: 4 years to 17 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies